Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 11—November 2003

Levofloxacin Treatment Failure in Haemophilus influenzae Pneumonia

Teresa Bastida*, María Pérez-Vázquez†, José Campos†, María Cristina Cortés-Lletget‡, Federico Román†, Fe Tubau§, Adela G. de la Campa†, and Carles Alonso-Tarrés‡Comments to Author 
Author affiliations: *Hospital de l´Esperit Sant, Santa Coloma de Gramenet, Barcelona, Spain; †Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain; ‡Hospital de l’Hospitalet, Consorci Sanitari Integral, L’Hospitalet de Llobregat, Barcelona, Spain; §Hospital “Prínceps d’Espanya” Ciutat Sanitària i Universitària de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

Main Article


Fluoroquinolone susceptibility and amino acid changes in GyrA, ParC, GyrB, and ParE QRDR fragments of three Haemophilus influenzae strains compared with a fully fluoroquinolone-susceptible straina

Strain no. MIC (µg/mL)
Amino acid at specified positions
ATCC 51907 0.007 0.03 0.01 0.003 84 Ser 88 Asp 84
Ser 420
32602, 35102, 35202 16 16 8 16 Leu Asn Ile Asn

aQRDR, quinolone resistance-determining regions; CIP, ciprofloxacin; LEV, levofloxacin; MOXI, moxifloxacin; GATI, gatifloxacin. Microdilution used for susceptibility testing (8).

Main Article

  1. Ball  P, Baquero  F, Cars  O, File  T, Garau  J, Klugman  K, Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother. 2002;49:3140. DOIPubMedGoogle Scholar
  2. Niederman  MS, Mandell  LA, Anzueto  A, Bass  JB, Broughton  WA, Campbell  GD, Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:173054.PubMedGoogle Scholar
  3. Lode  H, Allewelt  M. Role of newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother. 2002;49:70912. DOIPubMedGoogle Scholar
  4. Fenoll  A, Jado  I, Vicioso  D, Pérez  A, Casal  J. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain (1990 to 1996). J Clin Microbiol. 1998;36:344754.PubMedGoogle Scholar
  5. Campos  J, Chanyangam  M, deGroot  R, Smith  AL, Tenover  FC, Reig  R. Genetic relatedness of antibiotic resistance determinants in multiply resistant Haemophilus influenzae. J Infect Dis. 1989;160:8107. DOIPubMedGoogle Scholar
  6. Davidson  R, Cavalcanti  R, Brunton  JL, Bast  DJ, Azavedo  JCS, Kibsey  P, Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:74750. DOIPubMedGoogle Scholar
  7. Campos  J, Sáez-Nieto  JA. Gram negative infections: Haemophilus and other clinically relevant Gram negative coccobacilli. In: Cimolai N, editor. Laboratory diagnosis of bacterial infections. New York: Marcel Dekker, Inc; 2001. p. 557–80.
  8. Performance standards for antimicrobial susceptibility testing: eleventh informational supplement. Wayne (PA): National Committee for Clinical Laboratory Standards (NCCLS document no. M100–S11); 2001.
  9. Sánchez  L, Pan  W, Viñas  M, Nikaido  H. The acrAB homolog of H. influenzae codes for a functional multidrug efflux pump. J Bacteriol. 1997;179:68557.PubMedGoogle Scholar
  10. Campos  J, Román  F, Georgiou  M, García  C, Gómez-Lus  R, Cantón  R, Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. J Infect Dis. 1996;174:13457. DOIPubMedGoogle Scholar
  11. Fleischmann  RD, Adams  MD, White  O, Clayton  RA, Kirkness  EF, Kerlavage  AR, Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995;269:496512. DOIPubMedGoogle Scholar
  12. Georgiou  M, Muñoz  R, Román  F, Cantón  R, Gómez-Lus  R, Campos  J, Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrob Agents Chemother. 1996;40:17414.PubMedGoogle Scholar
  13. Pérez-Vázquez  M, Camacho  T, Román  F, Campos  J, Cantón  R. Mutations in quinolone-resistant determining regions (QRDR) of gyrA, gyrB, parC and parE genes in Haemophilus influenzae clinical isolates. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois; December 16–19, 2001; Abstract 145. Washington: American Society for Microbiology; 2001.
  14. Zhao  X, Drlica  K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 2001;33(Suppl 3):S14756. DOIPubMedGoogle Scholar
  15. Chien  SC, Rogge  MC, Gisclon  LG, Curtin  C, Wong  F, Natarajan  J, Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother. 1997;41:225660.PubMedGoogle Scholar

Main Article

Page created: April 20, 2012
Page updated: April 20, 2012
Page reviewed: April 20, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.